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During the 68th Annual Meeting of the 
Society of Investigative Dermatology,* 
more than 900 papers were presented 
via oral and poster presentations. The 
abstracts for the presentations were 
published in the Journal of Investigative 
Dermatology Supplement 1, in April 
2007. One of the most remarkable fea-
tures of this society meeting is the meld-
ing of both basic science and clinical 
research from a vast range of topics, 
including immunology, genetics, epide-
miology, structure and developmental 
biology, infectious diseases, photobiol-
ogy, and cancer biology. The following 
review of the meeting highlights a mere 
sampling of notable presentations.
IMMUNOLOGY
Antimicrobial peptides
Because the skin is the first defense 
against infectious and environmental 
agents, advances in understanding the 
immune response are critical for tack-
ling common skin disorders such as 
atopic dermatitis (AD). Robert Modlin 
(University of California, Los Angeles, 
CA) presented findings regarding the 
dependence of human vitamin D3-
induced antimicrobial activity against 
Mycobacterium tuberculosis on the 
antimicrobial peptide cathelicidin. 
Although his group has previously pub-
lished findings indicating that the acti-
vation of monocyte human Toll-like 
receptors (TLRs) induced cathelicidin 
expression and subsequent vitamin 
D receptor–dependent antimicro-
bial activity against this pathogen, Dr. 
Modlin furthered this remarkable story 
by describing the role of interleukin (IL)-
15 in the process. IL-15 is sufficient to 
induce the vitamin D synthesis path-
way. This cytokine is an important medi-
ator of TLR activation of the vitamin D 
receptor and cathelicidin and, as such, 
may be a great target for M. tuberculosis 
treatment. In addition, Jürgen Schauber 
(University of California, Davis, CA) 
presented evidence that injury enhanc-
es TLR2 function and antimicrobial 
peptide expression through a vitamin 
D–dependent mechanism. Again, the 
pathway involved IL-15.
Tissa Hata (University of California, 
Davis, CA) explored the function of cat-
helicidin in AD and psoriasis patients. 
Although AD patients are particularly 
susceptible to infection and inflam-
mation, expression of antimicrobial 
peptides is low in lesional skin from 
AD patients. In lesions from psoriasis 
patients, the peptide is expressed at high 
levels. Dr. Hata’s group probed the sys-
temic expression of cathelicidin. They 
found no correlation among cathelici-
din expression levels in skin, saliva, and 
blood, thereby supporting clinical obser-
vations of increased infection only in the 
skin of AD patients. These results support 
the manipulation of antimicrobial pep-
tides in the skin for the treatment of AD.
Barrier dysfunction
Additional insight into AD, a disease at 
the interface of allergy and immunol-
ogy, was provided by Donald Leung 
(National Jewish Medical and Research 
Center, Denver, CO) in the Julius Stone 
Lectureship. Dr. Leung described the 
complex interplay among genetics, 
immunology, and environmental fac-
tors that affect barrier dysfunction. 
Furthermore, he described the challenge 
presented by this common disease(17% 
of children are affected) to the potential 
of a mass smallpox vaccination cam-
paign. In normal patients, IL-37 selec-
tively kills vaccinia; however, in AD 
skin, dysregulated Th2 cytokines sup-
press the expression of IL-37 and pro-
mote vaccinia growth. Thus, treatment 
with anti-IL-4 or anti-IL-13 may stimu-
late the expression of IL-37 and permit 
effective immune response against vac-
cinia virus in AD skin.
Toll-like receptors and cancer
Damia Tormo (University of Bonn, 
Germany) described the therapeutic 
efficacy of antigen-specific vaccina-
tion and TLR stimulation against trans-
planted and autochthonous melanoma 
in mice. Stimulation of both the adap-
tive immune response via adenovirus 
transduction of antigen and the innate 
immune response via TLR ligand injec-
tion resulted in tumor rejection in a 
mouse model for invasive melanomas 
following neonatal carcinogen treat-
ment. Although the treatment delayed 
the growth of autochthonous primary 
melanomas in the mice, the tumors did 
not regress. These studies offer promis-
ing insights into the orchestration of an 
immune response for tumor immunity.
The protective effect of TLR4 against 
carcinogen-induced cutaneous tumori-
genesis in mice was described by 
Nabiha Yusuf (University of Alabama 
at Birmingham, AL). TLR4-deficient 
mice were treated with a carcinogenic 
polyaromatic hydrocarbon (DMBA). The 
mice developed contact hypersensitiv-
ity associated with carcinogenesis and 
exhibited increased IL-17, a proinflam-
matory cytokine often associated with 
allergies, as well as decreased interfer-
on-γ, a Th1 proinflammatory cytokine. 
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DMBA served as both an initiator and 
a promoter for tumorigenesis in these 
mice by increasing tumor number, inci-
dence, and size. Interestingly, DBMA 
treatment resulted in lower levels of 
IL-12, a cytokine that mediates tumor 
regression by inhibiting angiogenesis 
and promoting Th1 cytokine release and 
T-cell cytotoxicity. These results suggest 
that efforts to divert the cell-mediated 
immune response from IL-17 to inter-
feron-γ may ultimately prove beneficial 
in the prevention of skin tumors.
Interleukin-1β in the inflammasome
Lloyd Miller (University of California, 
Los Angeles, CA) discussed the role of 
IL-1β and the inflammasome in IL-1 
receptor–dependent neutrophil recruit-
ment during Staphylococcus aureus 
skin infection. Methicillin-resistant 
S. aureus is the most common cause of 
emergency room visits for skin infec-
tions and thus a critical health problem. 
This group previously reported that the 
IL-1 receptor was required to recruit 
neutrophils for clearance of this infec-
tion. The response was further examined 
in IL-1α-, IL-1β-, and IL-1α/1β-deficient 
mice. IL-1β was found to be responsible 
because deficient mice displayed larger 
lesions, defects in bacterial clearance, 
and impairment of neutrophil abscess. 
Thus, generation of IL-1β is a critical 
component for promotion of neutrophil 
clearance in S. aureus infection.
Interleukin-23 and psoriasis
In the inaugural Eugene Farber Lecture 
to honor the late renowned Stanford 
University professor of dermatology, 
Brian Nickoloff (Loyola University of 
Chicago Medical Center, IL) commem-
orated his colleague’s dedication to 
the combination of clinical and basic 
research on psoriasis with a description 
of his work on cytokine networking in 
psoriasis. The notion of a vast cytokine 
network and the nonrandom trafficking 
of immunocytes in psoriasis, a chronic 
inflammatory disease, was initially pro-
posed by Nickoloff more than a decade 
ago; however, recent efforts in multiple 
labs have supported this idea. Cytokines 
comprise the language that orches-
trates the cross-talk between immuno-
cytes and keratinocytes. In psoriasis, 
both IL-23 and Th17 responses play a 
role. Interestingly, healing of psoriatic 
plaques does not result in scar forma-
tion. Thus, the mechanism for termina-
tion of inflammation mediated by IL-23 
and Th17 remains an area for future 
scrutiny. In addition, Frank Nestle (King’s 
College London) described genetic and 
functional evidence for a role of the 
IL-23 pathway in the pathogenesis of 
psoriasis. Whole genome–association 
scans covering 300,000 markers were 
employed to identify genetic markers 
of psoriasis. A specific variation in IL-23 
receptor (R381Q) was found to be asso-
ciated with psoriasis. To validate these 
data, IL-23 blockade was shown to pre-
vent psoriasis in a humanized mouse 
skin graft model. As a result of the 
identification of the same IL-23 recep-
tor variant in irritable bowl syndrome, 
another inflammatory disease, this sig-
naling pathway is clearly earmarked as 
a therapeutic target.
GENE THERAPY
Therapy for epidermolysis bullosa
Gene therapy is a promising avenue for 
correction of defective genes implicated 
in a variety of skin diseases. Genetic 
defects in collage VII are responsible 
for recessive dystrophic epidermolysis 
bullosa (RDEB). J. Burnett (University of 
Southern California, Los Angeles, CA) 
described the use of a minigene encod-
ing the intact noncollagenous domains 
NC1 and NC2 and one half of the central 
collagenous domain of type VII collagen. 
The protein made from this minigene is 
very stable and retains the full function 
of collagen VII. In RDEB mice, injection 
of the short protein or lentiviral therapy 
with the minigene resulted in correction 
of blister formation, abrogation of base-
ment membrane separation, and restora-
tion of the anchoring fibrils. The protein 
therapy was found to be very promis-
ing and safe because treatment actu-
ally increased the survival of the mice. 
In addition, William Buitrago (Baylor 
College of Medicine, Houston, TX) pre-
sented his work on gene therapy to cor-
rect mutations in keratin 14 that disrupt 
filament integrity and cause Dowling-
Meara epidermolysis bullosa simplex 
(EBS), an autosomal dominant severe 
blistering disease. A mouse model that 
mimics EBS with expression of mutant 
keratin 14 in a small area of the skin 
via treatment with a topical inducer 
was developed. In these mice, mutant 
epidermal stem cells suffered a growth 
disadvantage compared with epidermal 
stem cells in which the keratin 14 muta-
tion had been corrected via lentiviral 
gene therapy. Moreover, the transduced 
cells were able to correct the EBS phe-
notype in vivo.
Systemic gene therapy via the skin
Jean-Philippe Therrien (National Cancer 
Institute, National Institutes of Health, 
Bethesda, MD) described a novel 
approach for the systemic delivery of 
genes by genetically modified human 
skin equivalents. A bicistronic vector 
containing the therapeutic antihyper-
tensive atrial natriuretic peptide gene 
linked to a multidrug-resistance select-
able marker was used. Transduced 
human skin equivalents were grafted to 
immunocompromised mice and sub-
jected to topical selection with colchi-
cine to select keratinocytes that express 
the marker. The atrial natriuretic peptide 
showed remarkable long-term expres-
sion, validating the use of this system for 
long-term systemic delivery of therapeu-
tic molecules via the skin.
UV DAMAGE, DNA REPAIR, AND 
GENOMIC INSTABILITY
Genotyping of melanomas
In the canonical DNA damage model, 
ultraviolet (UV) light damages DNA, and 
these lesions activate programs of cell 
cycle arrest, DNA repair, or apoptosis. If 
one of the checkpoints is bypassed due 
to error or mutation in a key factor, the 
cell may proliferate abnormally. Thus, 
cancer research has focused on under-
standing the implications of DNA dam-
age. In a state-of-the-art plenary lecture, 
Boris Bastian (University of California, 
San Francisco, CA) described somatic 
alterations in melanomas based on sites 
of sun exposure. Classifications of mela-
nomas from chronically sun-damaged, 
non-chronically sun-damaged, acral, 
or mucosal sites revealed differences in 
genotype, with mutations in oncogenic 
BRAF occurring in non-chronically 
sun-damaged sites and mutations in 
the oncogene Kit occurring at the other 
sites. In addition, melanomas at sites 
protected from chronic sun exposure 
were more likely to exhibit genomic 
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instability. These interesting findings sug-
gest that clinical melanomas result from 
different molecular mechanisms.
NF-κB induction in SCC
David Bickers (Columbia University, 
New York, NY), who specializes in study-
ing the role of carcinogens such as UV 
radiation in skin cancer, demonstrated 
that the blockade of nuclear factor kappa 
B (NF-κB), which typically drives prolifer-
ation and resistance to apoptosis, inhib-
its UVB-induced photocarcinogenesis in 
murine skin. Squamous-cell carcinomas 
(SCCs) and basal-cell carcinomas (BCCs) 
are induced by UVB concomitant with 
inactivation of p53. Activation of NF-κB 
is a common feature of SCC in human 
skin. When Bickers’ group blocked NF-
κB with a specific inhibitor (pyrrolidine 
dithiocarbamate), NF-κB did not trans-
locate to the nucleus. Following UVB 
exposure, the mice exhibited delayed 
tumor formation, decreased incidence 
of tumors, and decreased tumor size. 
Diminished expression of NF-κB down-
stream targets and proliferation markers 
and increased expression of apoptosis 
executor caspase-3 indicated that UVB-
induced NF-κB is critical for the patho-
genesis of SCCs.
Telomeres in genetic stability
Telomeres have also been a hot topic 
for research lately because faulty repli-
cation of these terminal chromosomal 
sequences may result in senescence, 
elicit a DNA damage response, or 
cause genomic instability. Advances in 
understanding the pathways involved in 
maintaining this fidelity have aided our 
understanding of DNA repair, aging, and 
tumorigenesis. Thomas Rünger (Boston 
University, MA) presented work on 
the role of the Fanconi anemia/BRCA1 
pathway in telomere loop opening and 
closing. Although the Fanconi anemia 
pathway is activated in response to DNA 
damage, the pathway is interestingly 
activated in the absence of damage in 
late S phase. The addition of oligonucle-
otides with homology to telomere ends 
(T-oligos) also induces this activation and 
elicits formation of foci containing the 
DNA damage/repair factors, FANCD2, 
BRCA1, γH2AX, and RAD51. These 
complexes may play a role in telomere 
D loop opening to complete replication.
Mark Eller (Boston University, MA) 
described a mechanism for protection 
of genomic integrity in the face of telo-
mere replication. Telomeres employ 
a loop structure to cap chromosome 
ends in order to protect the ends from 
recognition by DNA damage sensors. 
Because T-oligos mimic free telomeric 
ends, these sequences induce a DNA 
damage response and generate foci that 
include typical DNA damage respond-
ers. WRN is the helicase mutated in 
Werner’s syndrome, a disease charac-
terized by premature aging and predis-
position to cancer. This helicase, which 
preferentially binds to DNA hairpins, G 
quadruplexes, and telomere loop struc-
tures, is required for the foci formation. 
In fact, knockdown of WRN activity 
reduces T-oligo activity. Taken together, 
the evidence implicates WRN in recog-
nition of uncapped telomere ends, sig-
naling of replicative stress, initiation of 
proliferation arrest, and recruitment of 
DNA repair complexes to telomeres.
Telomere sequences affect angiogenesis
In addition to activating a DNA damage 
response, T-oligos have been implicated 
in inhibition of tumor angiogenesis and 
melanoma growth. D. Levine (Boston 
University, MA) demonstrated that T-
oligo treatment of mice bearing human 
melanoma cell xenografts significantly 
decreased the potent angiogenic factor 
VEGF and the expression of the VEGF 
receptor. In addition, T-oligo treatment 
also increased the transcription fac-
tor E2F1, which is known to promote 
apoptosis and negatively regulate pro-
angiogenic factors. The treatment also 
decreased endothelial tube formation, 
invasion by melanoma cells, and tumor 
volume. Thus, T-oligos negatively regu-
late tumor angiogenesis and cooper-
ate with proapoptotic factors to reduce 
melanoma growth in vivo. Although the 
exact mechanism of this effect is not 
completely clear, T-oligos may provide 
a novel therapy for melanomas.
CELL SIGNALING AND DEVELOPMENT
Wnt signaling
Complex regulatory cell signaling 
drives cell proliferation, differentiation, 
and function. In a state-of-the-art ple-
nary lecture, Sarah Millar (University 
of Pennsylvania, Philadelphia, PA) pre-
sented evidence for Wnt signaling in the 
development of skin appendages includ-
ing hair follicles, teeth, and mammary 
glands. Not only is this pathway required 
for the initiation of postnatal develop-
ment of hair follicles and mammary 
glands, but this signaling is also critical 
for embryonic tooth and tongue taste-
papillae development. Moreover, in 
the William Montagna Lecture, George 
Cotsarelis (University of Pennsylvania, 
Philadelphia, PA) presented new find-
ings regarding hair-follicle stem cells 
and hair regeneration. Despite contrary 
findings published more than 50 years 
ago, the central dogma in cutaneous 
biology asserts that hair follicles form 
only during development and thus adult 
hair-follicle loss is permanent. However, 
hair-follicle regeneration was recently 
observed following re-epithelializa-
tion after wounding in mice. Although 
cells from the hair bulge contributed to 
the re-epithelialization, genetic label-
ing experiments revealed that the new 
hair follicles derive exclusively from the 
interfollicular epidermal cells. In addi-
tion, this hair follicle neogenesis was 
found to be dependent on the Wnt sig-
naling pathway. These exciting results 
herald a novel regenerative potential for 
mammals and offer promise for clini-
cal management of alopecia and tissue 
engineering.
In addition, E. Moore (University of 
Washington, Seattle, WA) revealed that 
Wnt/β-catenin signaling plays a very dif-
ferent role in melanoma than in colon 
cancer. Murine and human melanoma 
cell lines overexpressing Wnt3a or -5a 
showed that activation of this pathway 
negatively regulates tumor growth and 
decreases proliferation. These findings 
are in stark contrast with the deleterious 
effects observed with β-catenin activa-
tion in colon cancer. In the future, the 
Wnt/β-catenin pathway may be target-
ed for melanoma treatment or serve as 
prognostic markers.
Hedgehog signaling in BCC
In a state-of-the-art plenary lecture, 
Andrzej Dlugosz (University of 
Michigan, Ann Arbor, MI) discussed 
hedgehog signaling, a pathway critical 
for both development and regulation of 
hair follicles. Activation of the hedgehog 
pathway is important and perhaps 
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sufficient for development of BCC. In a 
“gene switch” mouse model, hedgehog 
signaling deactivation resulted in robust 
regression of BCCs. Thus, hedgehog 
signaling antagonists, including cyclop-
amide, may serve as a treatment target 
for both BCC and medulloblastomas.
Lipid biosynthesis in epidermal barrier 
function
Yoshikazu Uchida (University of 
California, San Francisco, CA) presented 
work honored by the Nature Publishing 
Group as the most outstanding abstract 
in the basic sciences. Ceramides are 
critical components for epidermal per-
meability barrier function. Mutations in 
ELOVL4, a fatty acid elongation enzyme, 
are associated with macular degenera-
tion. Because this gene is also expressed 
in the skin, the group examined mice 
homozygous for these mutations and 
found that they exhibit compromised 
epidermal permeability barrier, deficient 
epidermal lamellar body content, signif-
icant decreases in very-long-chain fatty 
acids, and a lack of epidermal ω-O-acyl-
ceramide and its immediate precursor. 
The results demonstrate that ELOVL4 is 
required for generation of very long fatty 
acids that are critical not only for epider-
mal barrier formation but also for mam-
malian survival.
DIAGNOSTICS AND CLINICAL 
RESEARCH
Prenatal diagnostics
In a state-of-the-art plenary lecture, 
John McGrath (King’s College London) 
described the state of prenatal diag-
nostic testing for inherited skin disor-
ders. Fetal skin biopsy, chorionic villi 
sampling, and preimplantation genetic 
diagnosis have been employed to diag-
nose EB at earlier and earlier stages of 
development. Noninvasive embryo 
testing is on the horizon as researchers 
learn more about collecting and analyz-
ing short fragments of fetal DNA and 
RNA present in maternal blood as early 
as 18 days after embryo transfer.
Noninvasive diagnostics for melanoma
William Wachsman conveyed a pioneer-
ing effort to differentiate melanoma from 
dysplastic nevi in suspicious pigmented 
skin lesions using a novel noninvasive 
tape stripping method. This work was 
also honored by the Nature Publishing 
Group for innovative research in the 
clinical research sector. Although the 
gold standard of melanoma diagnosis is 
histopathology of biopsied tissue, these 
researchers employed their Epidermal 
Genetic Information Retrieval system 
(EGIR) to analyze stratum corneum RNA 
from pigmented lesions. This simple 
noninvasive method provided RNA for 
amplification and microarray analysis. 
In trials, approximately 88 genes were 
discriminators between melanoma and 
dysplastic nevi. This study demonstrated 
that EGIR-harvested RNA can be used to 
differentiate melanoma from dysplastic 
nevi and that the stratum corneum gene 
profile is, in fact, altered in melanoma.
Novel wound-closure method
Irene Kochevar (Harvard University, 
Boston, MA) presented evidence sup-
porting photochemical tissue bonding 
as an alternative to sutures or glue for 
closure of skin excisions and incisions. 
Photochemical tissue bonding involves 
application of Rose Bengal dye to the 
wound site and subsequent exposure 
to green light. The resultant watertight 
seal stems from chemical linkage of sur-
face collagen molecules. Although Rose 
Bengal is known to generate phototoxic 
singlet oxygen molecules, this method 
produced no thermal damage, no cell 
toxicity, and no increased inflammation. 
Together these attributes suggest that 
this method may be useful for wound 
closure and may even lead to reduced 
scarring.
UVA photoadaptation
Another method of phototherapy is 
employed to treat scleroderma, a con-
dition involving increased collagen 
deposition in the dermis. This thera-
py is remarkably successful in some 
patients, but others do not respond. 
Frank Wang (University of Michigan, 
Ann Arbor, MI) demonstrated that pho-
toadaptation diminishes the in vivo 
antifibrotic response to UVA1 photo-
therapy. By testing the effects on tan-
ning and matrix metalloproteinase 1 
induction, this group found that the 
lightest skin responds well to UVA1 
treatment with upregulation of the 
proteinase; however, treatment results 
in darkening of the skin and a subse-
quent diminished response. Clinically, 
the findings support further investiga-
tion to determine whether UVA1 is, in 
fact, better suited to light-skinned indi-
viduals or whether lower doses may 
minimize increased pigmentation in 
response to phototherapy.
Conclusions
Two speakers gave futuristic presen-
tations. Stuart Schreiber (Harvard 
University, Boston, MA), who pre-
sented the Herman Beerman Lecture, 
described the building of a small-
molecule drug-discovery pipeline. In 
addition, the remarkable data-sharing 
network of ChemBank (http://chem-
bank.broad.harvard.edu), which focus-
es on target identification via compara-
tive analysis of small molecules in bio-
logical assays, was demonstrated. In the 
Naomi Kanof Lecture, which empha-
sizes scientific achievement outside 
the skin, Thomas Pearson (University of 
Rochester, NY) chronicled the global 
pandemic of cardiovascular disease 
from the standpoints of epidemiology 
and preventive medicine. This presen-
tation depicted cardiovascular disease 
in developed and developing countries 
and highlighted trends in risk factors 
and prevention.
The primary goals of the Society 
for Investigative Dermatology are to 
promote the science relevant to skin 
health and disease and to provide 
education and scholarly exchange of 
scientific data. The annual meeting of 
the Society furthers these objectives by 
bringing together diverse researchers 
and engaging them in critical assimila-
tion of the state-of-the-art results in the 
field. Combining invited lectures and 
submitted presentations from around 
the world with sponsored satellite sym-
posia, educational tracks for residents 
and fellows, and breakout symposia, 
this meeting clearly met the goals.
*The 68th Annual Meeting of the Society of 
Investigative Dermatology was held at the 
Hyatt Regency Century Plaza Hotel in Los 
Angeles, California, USA, 9–12 May 2007.
